Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2019 Dec;7(Suppl 8):S330.
doi: 10.21037/atm.2019.09.117.

The SONAR study-is there a future for endothelin receptor antagonists in diabetic kidney disease?

Avivit Cahn  1 , Simona Cernea  2   3 , Itamar Raz  1
Affiliations
Editorial

The SONAR study-is there a future for endothelin receptor antagonists in diabetic kidney disease?

Avivit Cahn et al. Ann Transl Med. 2019 Dec.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: AC reports grants and personal fees from AstraZeneca and Novo Nordisk and personal fees from Eli Lilly, Medial EarlySign, Abbott, Gefen Medical, Sanofi, Boehringer Ingelheim, Merck Sharp & Dohme, and GlucoMe. SC received payment for lectures from AstraZeneca, Boehringer Ingelheim, Berlin-Chemie Menarini, Eli Lilly, MSD, Novo Nordisk, Sanofi, Servier Pharma, for clinical trial Steering Committee meetings as National Lead Investigator for DECLARE-TIMI58 from TIMI Study Group, consultant fees for Advisory Board from AstraZeneca and support for travel to meetings from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Sanofi, MSD, Novo Nordisk, Worwag Pharma. IR reports personal fees from AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Concenter BioPharma and Silkim, Eli Lilly, Merck Sharp & Dohme, Novo Nordisk, Orgenesis, Pfizer, Sanofi, SmartZyme Innovation, Panaxia, FuturRx, Insuline Medical, Medial EarlySign, CameraEyes, Exscopia, Dermal Biomics, Johnson & Johnson, Novartis, Teva, GlucoMe, and DarioHealth.

Comment on

References

    1. American Diabetes Association Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes-2019. Diabetes Care 2019;42:S124-38. 10.2337/dc19-S011 - DOI - PubMed
    1. Umanath K, Lewis JB. Update on Diabetic Nephropathy: Core Curriculum 2018. Am J Kidney Dis 2018;71:884-95. 10.1053/j.ajkd.2017.10.026 - DOI - PubMed
    1. Anders HJ, Huber TB, Isermann B, Schiffer M. CKD in diabetes: diabetic kidney disease versus nondiabetic kidney disease. Nat Rev Nephrol 2018;14:361-77. 10.1038/s41581-018-0001-y - DOI - PubMed
    1. Koye DN, Magliano DJ, Nelson RG, Pavkov ME. The Global Epidemiology of Diabetes and Kidney Disease. Adv Chronic Kidney Dis 2018;25:121-32. 10.1053/j.ackd.2017.10.011 - DOI - PMC - PubMed
    1. Heerspink HJL, Greene T, Tighiouart H, et al. Chronic Kidney Disease Epidemiology Collaboration Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials. Lancet Diabetes Endocrinol 2019;7:128-39. 10.1016/S2213-8587(18)30314-0 - DOI - PubMed